BioNTech Co-Founders Depart to Launch Next-Gen mRNA Therapeutics Venture

Two of BioNTech’s co-founders have officially resigned from their executive positions to launch a new biotechnology company dedicated to expanding the therapeutic applications of mRNA technology beyond infectious diseases. The founders, whose names are not disclosed in public filings, are leading a newly incorporated entity focused on targeting chronic conditions such as autoimmune disorders and cancer immunotherapies. The new venture has already secured $150 million in initial funding from a consortium of private investors, including major life sciences-focused venture capital firms. The leadership transition comes amid growing scrutiny of BioNTech’s R&D trajectory following the post-pandemic slowdown in its vaccine pipeline. While BioNTech’s stock (BNTX) has traded within a narrow range over the past 12 months, the exodus of key founders has prompted market reassessment. Analysts note that the move could accelerate innovation in the mRNA space, particularly as rival companies like Vertex Pharmaceuticals (VRTX) and Pfizer (PFE) continue to expand their own mRNA portfolios. BioNTech remains committed to its current pipeline, with two Phase 3 trials underway for a personalized cancer vaccine and a novel mRNA-based treatment for type 1 diabetes. However, the departure of its co-founders—individuals instrumental in the company’s 2020 breakthrough—has raised questions about long-term strategic direction. The new venture is expected to begin clinical-stage development by late 2026, with potential partnerships anticipated with global pharma firms. Market reaction has been mixed. BNTX shares dipped 3.2% in early trading, while VRTX gained 1.8% on speculation of increased competition and collaboration opportunities. PFE, which has a longstanding mRNA collaboration with BioNTech, saw no immediate change in valuation despite the leadership shift.